Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin.

No abstract is available for this paper.

• Publication year

  1982

• Venue

  Biochemical Journal

• Publication date

  1982-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1042/BJ2070381PMID 7165698PMCID PMC1153876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heterogeneity of somatostatin like immunoreactivity (SLI) in extracts of porcine, canine and human pancreas.

  1981cited by this paper
• Evidence for Transformation of Glucagon-Like Immunoreactivity of Gut into Pancreatic Glucagon In Vivo

  1981cited by this paper
• Relationship of glicentin to proglucagon and glucagon in the porcine pancreas

  1981cited by this paper
• The primary structure of porcine glicentin (proglucagon).

  1981cited by this paper
• Evidence that glicentin contains the entire sequence of glucagon.

  1980cited by this paper
• Hormone receptors in digestion and nutrition : proceedings of the second International Symposium on Hormonal Receptors in Digestive Tract Physiology, held in Montpellier (France) May 3-5, 1979

  1979cited by this paper
• Extrapancreatic glucagons.

  1978cited by this paper
• Extraction, gel filtration pattern, and receptor binding of porcine gastrointestinal glucagon-like immunoreactivity

  1977cited by this paper
• Purification and Characterization of a Protein from Porcine Gut with Glucagon-Like Immunoreactivity

  1976cited by this paper
• A radioreceptor-assay for glucagon: Binding of enteroglucagon to liver plasma membranes

  1975cited by this paper
• Purification of 125 I-glucagon by anion exchange chromatography.

  1972cited by this paper

• Bifidobacterium longum subsp. longum B-53 Alleviated Abnormalities of Glycolipid Metabolism and Oxidative Stress in T2DM Mice Through Regulating Gut Microbiota and GLP-1 Secretion.

  2025cites this paper
• Oxyntomodulin-past, present and future.

  2025cites this paper
• β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes.

  2025cites this paper
• Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes

  2024cites this paper
• Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

  2023cites this paper
• Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity.

  2023cites this paper
• Signs of Glucagon Resistance After a Two-Week Hypercaloric Diet Intervention.

  2023cites this paper
• Discovery of the GI Effects of GLP-1: An Historical Perspective

  2022cites this paper
• Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

  2022influential citation
• Effect of 6 weeks of very low-volume high-intensity interval training on oral glucose-stimulated incretin hormone response

  2021cites this paper
• Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study

  2021cites this paper
• On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA

  2021cites this paper
• Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

  2020cites this paper
• Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study

  2020cites this paper
• No evidence of tachyphylaxis for insulinotropic actions of Glucose-Dependent Insulinotropic Polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects.

  2020cites this paper
• Plasma glucagon levels measured by sandwich ELISA are correlated with impaired glucose tolerance in type 2 diabetes.

  2020cites this paper
• Paracrine Crosstalk between Intestinal L- and D-cells Controls Secretion of Glucagon-Like Peptide-1 in mice.

  2019cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease

  2019cites this paper
• The metabolic sequelae of oesophago-gastric resection

  2019cites this paper
• From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy

  2019cites this paper
• The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults

  2019cites this paper
• Methods and Guidelines for Measurement of Glucagon in Plasma

  2019cites this paper
• Oxyntomodulin: Actions and role in diabetes

  2018cites this paper
• Impact of C-Peptide Status on the Response of Glucagon and Endogenous Glucose Production to Induced Hypoglycemia in T1DM

  2018cites this paper
• Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals

  2017cites this paper
• Discovery, characterization, and clinical development of the glucagon-like peptides.

  2017cites this paper
• Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation

  2016cites this paper
• The incretin hormones, glucose-dependent insulinotropic poly- peptide (GIP) and glucagon-like peptide-1 (GLP-1), are gut hor- mones secreted from enteroendocrine cells in the intestinal mu- cosa. They act as key regulators-in a glucose-dependent fashion-of pancreatic alpha and beta cell secretion in

  2016cites this paper
• Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial

  2015cites this paper
• Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure.

  2015cites this paper
• Incretin and glucagon levels in adult offspring exposed to maternal diabetes in pregnancy.

  2015cites this paper
• Autonomic Diabetic Neuropathy Impairs Glucose and Dipeptidyl Peptidase 4 Inhibitor-Regulated Glucagon Concentration in Type 1 Diabetic Patients

  2015cites this paper
• Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

  2014cites this paper
• Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients.

  2014cites this paper
• The incretin effect does not differ in trained and untrained, young, healthy men

  2014cites this paper
• No Effect of Aprotinin (Trasylol™) on Degradation of Exogenous and Endogenous Glucagon in Human, Mouse and Rat Plasma

  2014cites this paper
• Targeting the intestinal L-cell for obesity and type 2

  2014cites this paper
• Possible metabolic impact of Ramadan fasting in healthy men.

  2014cites this paper
• Targeting the intestinal L-cell for obesity and type 2 diabetes treatment

  2014cites this paper
• Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.

  2014cites this paper
• Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans.

  2014cites this paper
• oxyntomodulin measurement in human 2

  2014cites this paper
• Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.

  2013cites this paper
• Complex Multi-Block Analysis Identifies New Immunologic and Genetic Disease Progression Patterns Associated with the Residual β-Cell Function 1 Year after Diagnosis of Type 1 Diabetes

  2013cites this paper
• RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.

  2013cites this paper
• Appetite regulation in overweight, sedentary men after different amounts of endurance exercise: a randomized controlled trial.

  2013cites this paper
• Meal induced gut hormone secretion is altered in aerobically trained compared to sedentary young healthy males

  2013cites this paper
• Acute differential effects of dietary protein quality on postprandial lipemia in obese non-diabetic subjects.

  2013cites this paper
• Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study

  2012cites this paper
• Unraveling oxyntomodulin, GLP1's enigmatic brother

  2012cites this paper
• Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.

  2012cites this paper
• Exenatide plus metformin compared with metformin alone on β‐cell function in patients with Type 2 diabetes

  2012cites this paper
• Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

  2012cites this paper
• Proinsulin, GLP‐1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes

  2012cites this paper
• Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.

  2012cites this paper
• Effects of different fractions of whey protein on postprandial lipid and hormone responses in type 2 diabetes

  2012cites this paper
• A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function

  2012cites this paper
• Acute differential effects of milk-derived dietary proteins on postprandial lipaemia in obese non-diabetic subjects

  2012cites this paper
• Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients

  2012cites this paper
• Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeks’ sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial

  2011cites this paper
• GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes

  2011cites this paper
• Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides.

  2011cites this paper
• Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.

  2011cites this paper
• Counter‐regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double‐blinded randomized cross‐over study

  2011cites this paper
• Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

  2011cites this paper
• Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion

  2011cites this paper
• Gastric emptying, glucose metabolism and gut hormones: evaluation of a common preoperative carbohydrate beverage.

  2011cites this paper
• The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

  2011cites this paper
• Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes

  2011cites this paper
• On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans.

  2010cites this paper
• Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis.

  2010cites this paper
• Acute effects of casein on postprandial lipemia and incretin responses in type 2 diabetic subjects.

  2010cites this paper
• The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

  2010cites this paper
• Oxyntomodulin increases the concentrations of insulin and glucose in plasma but does not affect ghrelin secretion in Holstein cattle under normal physiological conditions.

  2010cites this paper
• Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.

  2010cites this paper
• The T-Allele of TCF7L2 rs7903146 Associates With a Reduced Compensation of Insulin Secretion for Insulin Resistance Induced by 9 Days of Bed Rest

  2010cites this paper
• Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?

  2010cites this paper
• Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes.

  2010cites this paper
• Automated detection of hypoglycemia-induced EEG changes recorded by subcutaneous electrodes in subjects with type 1 diabetes--the brain as a biosensor.

  2010cites this paper
• Glucagon and glucagon-like peptides 1 and 2.

  2010cites this paper
• Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets.

  2010cites this paper
• Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes.

  2010cites this paper
• Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test

  2010cites this paper
• Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.

  2010cites this paper
• Differential incretin effects of GIP and GLP‐1 on gastric emptying, appetite, and insulin‐glucose homeostasis

  2010cites this paper
• The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men

  2009cites this paper
• Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

  2009cites this paper
• Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein.

  2009cites this paper
• No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon‐like‐peptide‐1 administration in fasting healthy subjects

  2009cites this paper
• Short-term treatment with Olanzapine does not modulate gut hormone

  2009cites this paper
• Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action

  2008cites this paper
• Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance

  2008cites this paper
• Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

  2008cites this paper
• Porcine glucagon-like peptide-2: structure, signaling, metabolism and effects.

  2008cites this paper
• The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period

  2008cites this paper
• Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans

  2008cites this paper
• Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact on glucose regulatory hormones and the growth hormone/insulin-like growth factor-I axis.

  2008cites this paper
• Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

  2007cites this paper
• Preserved GLP-1 effects in a diabetic patient with Cushing's disease.

  2007cites this paper